Lantheus (NASDAQ:LNTH) Reaches New 12-Month High – What’s Next?

Lantheus Holdings, Inc. (NASDAQ:LNTH) shares hit a new 52-week high during mid-day trading on Friday . The stock traded as high as $104.00 and last traded at $102.8650, with a volume of 268369 shares. The stock had previously closed at $102.82.

Analyst Upgrades and Downgrades

LNTH has been the topic of several recent research reports. Citigroup reaffirmed an “outperform” rating on shares of Lantheus in a research note on Friday, May 8th. JonesTrading cut shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Friday, February 27th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $94.00 target price on shares of Lantheus in a research note on Thursday, May 7th. B. Riley Financial reiterated a “buy” rating on shares of Lantheus in a report on Friday, May 1st. Finally, William Blair reiterated an “outperform” rating on shares of Lantheus in a report on Tuesday, March 17th. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $101.86.

Lantheus Stock Performance

The company has a current ratio of 2.83, a quick ratio of 2.64 and a debt-to-equity ratio of 0.47. The firm has a fifty day moving average price of $87.50 and a 200 day moving average price of $74.77. The firm has a market cap of $6.56 billion, a PE ratio of 24.30 and a beta of -0.03.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 EPS for the quarter, topping the consensus estimate of $1.25 by $0.21. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The business had revenue of $377.33 million for the quarter, compared to analyst estimates of $354.48 million. During the same quarter in the previous year, the firm earned $1.53 EPS. The company’s quarterly revenue was up 1.2% compared to the same quarter last year. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, equities research analysts expect that Lantheus Holdings, Inc. will post 4.41 earnings per share for the current fiscal year.

Institutional Trading of Lantheus

Several institutional investors and hedge funds have recently bought and sold shares of LNTH. M&T Bank Corp purchased a new stake in Lantheus in the 4th quarter valued at about $370,950,000. Farallon Capital Management LLC raised its holdings in Lantheus by 56.1% in the 4th quarter. Farallon Capital Management LLC now owns 5,427,479 shares of the medical equipment provider’s stock valued at $361,199,000 after buying an additional 1,950,252 shares during the period. Norges Bank purchased a new stake in Lantheus in the 4th quarter valued at about $76,197,000. Freestone Grove Partners LP raised its holdings in Lantheus by 4,114.8% in the 4th quarter. Freestone Grove Partners LP now owns 608,526 shares of the medical equipment provider’s stock valued at $40,497,000 after buying an additional 594,088 shares during the period. Finally, Healthcare of Ontario Pension Plan Trust Fund raised its holdings in Lantheus by 686.1% in the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 598,857 shares of the medical equipment provider’s stock valued at $45,423,000 after buying an additional 522,678 shares during the period. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.